解锁Alpelisib在乳腺癌中的潜力:综合综述。

Q4 Medicine
Siddhi M Chandak, Manoj R Kumbhare, Vrushali P Patole
{"title":"解锁Alpelisib在乳腺癌中的潜力:综合综述。","authors":"Siddhi M Chandak, Manoj R Kumbhare, Vrushali P Patole","doi":"10.62958/j.cjap.2025.005","DOIUrl":null,"url":null,"abstract":"<p><p>Alpelisib is a cancer therapy drug that has shown significant promise in the treatment of certain types of cancer. Its pharmacokinetics and pharmacodynamics indicate that it is absorbed better orally and has a prolong half-life, allowing for once-every day dosing. Currently, its mechanism of action is established to be the suppression of phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), which is the pivotal enzyme of PI3K pathway, which is abnomal in most cancers. The chemistry of alpelisib involves its selective inhibition of PI3K, targeting specifically HR-positive, HER2-negative breast cancer with PIK3CA mutations. The common side effects associated with alpelisib include fever, peripheral edema, fatigue, headache, skin rash, alopecia, pruritis, hyperglycemia, increased gamma-glutamyl transferase, decreased serum calcium, weight loss, diarrhea, nausea, increased serum lipase, decreased appetite, stomatitis, vomiting, dysgeusia, lymphocytopenia, prolonged PTT, and increased serum creatinine. The use of alpelisib in cancer therapy is being extensively studied through various clinical trials, aiming to determine the optimal patient populations for treatment and explore alternative tumor indications and drug combine regimens.</p>","PeriodicalId":23985,"journal":{"name":"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","volume":"41 ","pages":"e20250005"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unlocking the Potential of Alpelisib in Breast Cancer: A Comprehensive Review.\",\"authors\":\"Siddhi M Chandak, Manoj R Kumbhare, Vrushali P Patole\",\"doi\":\"10.62958/j.cjap.2025.005\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Alpelisib is a cancer therapy drug that has shown significant promise in the treatment of certain types of cancer. Its pharmacokinetics and pharmacodynamics indicate that it is absorbed better orally and has a prolong half-life, allowing for once-every day dosing. Currently, its mechanism of action is established to be the suppression of phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), which is the pivotal enzyme of PI3K pathway, which is abnomal in most cancers. The chemistry of alpelisib involves its selective inhibition of PI3K, targeting specifically HR-positive, HER2-negative breast cancer with PIK3CA mutations. The common side effects associated with alpelisib include fever, peripheral edema, fatigue, headache, skin rash, alopecia, pruritis, hyperglycemia, increased gamma-glutamyl transferase, decreased serum calcium, weight loss, diarrhea, nausea, increased serum lipase, decreased appetite, stomatitis, vomiting, dysgeusia, lymphocytopenia, prolonged PTT, and increased serum creatinine. The use of alpelisib in cancer therapy is being extensively studied through various clinical trials, aiming to determine the optimal patient populations for treatment and explore alternative tumor indications and drug combine regimens.</p>\",\"PeriodicalId\":23985,\"journal\":{\"name\":\"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology\",\"volume\":\"41 \",\"pages\":\"e20250005\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.62958/j.cjap.2025.005\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62958/j.cjap.2025.005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

Alpelisib是一种癌症治疗药物,在治疗某些类型的癌症方面显示出显著的前景。其药代动力学和药效学表明,口服吸收更好,半衰期延长,允许每天服用一次。目前确定其作用机制是抑制磷脂酰肌醇- 4,5 -二磷酸3-激酶催化亚单位α (PIK3CA), PI3K途径的关键酶,在大多数癌症中都是异常的。alpelisib的化学作用包括选择性抑制PI3K,特异性靶向hr阳性、her2阴性的PIK3CA突变乳腺癌。与alpelisib相关的常见副作用包括发热、周围水肿、疲劳、头痛、皮疹、脱发、瘙痒、高血糖、γ -谷氨酰转移酶升高、血清钙降低、体重减轻、腹泻、恶心、血清脂肪酶升高、食欲下降、口炎、呕吐、吞咽困难、淋巴细胞减少、PTT延长和血清肌酐升高。alpelisib在癌症治疗中的应用正在通过各种临床试验进行广泛研究,旨在确定治疗的最佳患者群体,探索替代的肿瘤适应症和药物联合治疗方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Unlocking the Potential of Alpelisib in Breast Cancer: A Comprehensive Review.

Alpelisib is a cancer therapy drug that has shown significant promise in the treatment of certain types of cancer. Its pharmacokinetics and pharmacodynamics indicate that it is absorbed better orally and has a prolong half-life, allowing for once-every day dosing. Currently, its mechanism of action is established to be the suppression of phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), which is the pivotal enzyme of PI3K pathway, which is abnomal in most cancers. The chemistry of alpelisib involves its selective inhibition of PI3K, targeting specifically HR-positive, HER2-negative breast cancer with PIK3CA mutations. The common side effects associated with alpelisib include fever, peripheral edema, fatigue, headache, skin rash, alopecia, pruritis, hyperglycemia, increased gamma-glutamyl transferase, decreased serum calcium, weight loss, diarrhea, nausea, increased serum lipase, decreased appetite, stomatitis, vomiting, dysgeusia, lymphocytopenia, prolonged PTT, and increased serum creatinine. The use of alpelisib in cancer therapy is being extensively studied through various clinical trials, aiming to determine the optimal patient populations for treatment and explore alternative tumor indications and drug combine regimens.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
0.70
自引率
0.00%
发文量
53
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信